Morgan Stanley
BLCM

Morgan Stanley’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Morgan Stanley’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,962
Closed -$4.61K – 7777
2023
Q1 		$4.61K Buy
13,962
+279
+2% +$258 ﹤0.01% 7065
2022
Q4 		$9.85K Buy
13,683
+5,013
+58% +$4.96K ﹤0.01% 6942
2022
Q3 		$10K Sell
8,670
-1,378
-14% -$1.76K ﹤0.01% 7085
2022
Q2 		$12K Sell
10,048
-287
-3% -$434 ﹤0.01% 7171
2022
Q1 		$22K Buy
10,335
+4,717
+84% +$7.67K ﹤0.01% 7117
2021
Q4 		$8K Sell
5,618
-1
-0% -$2 ﹤0.01% 7550
2021
Q3 		$16K Buy
5,619
+803
+17% +$2.45K ﹤0.01% 7183
2021
Q2 		$16K Buy
4,816
+3,956
+460% +$12.7K ﹤0.01% 7085
2021
Q1 		$3K Sell
860
-2,201
-72% -$9.57K ﹤0.01% 7235
2020
Q4 		$11K Sell
3,061
-32
-1% -$135 ﹤0.01% 6615
2020
Q3 		$20K Buy
3,093
+2,138
+224% +$14.5K ﹤0.01% 6075
2020
Q2 		$7K Sell
955
-23,770
-96% -$162K ﹤0.01% 6254
2020
Q1 		$116K Buy
24,725
+18,676
+309% +$200K ﹤0.01% 5128
2019
Q4 		$78K Buy
6,049
+5,104
+540% +$47.1K ﹤0.01% 5734
2019
Q3 		$10K Sell
945
-25,257
-96% -$330K ﹤0.01% 6216
2019
Q2 		$445K Sell
26,202
-2,732
-9% -$73.9K ﹤0.01% 4664
2019
Q1 		$975K Sell
28,934
-5,731
-17% -$192K ﹤0.01% 4123
2018
Q4 		$1.01M Sell
34,665
-620
-2% -$27.5K ﹤0.01% 4268
2018
Q3 		$2.17M Sell
35,285
-2,557
-7% -$173K ﹤0.01% 3938
2018
Q2 		$2.79M Buy
37,842
+1,625
+4% +$127K ﹤0.01% 3770
2018
Q1 		$2.38M Buy
36,217
+10,909
+43% +$824K ﹤0.01% 3832
2017
Q4 		$2.13M Sell
25,308
-11,759
-32% -$1.15M ﹤0.01% 3982
2017
Q3 		$4.28M Buy
37,067
+12,137
+49% +$1.28M ﹤0.01% 3132
2017
Q2 		$2.91M Sell
24,930
-12,532
-33% -$1.56M ﹤0.01% 3433
2017
Q1 		$4.62M Sell
37,462
-5,585
-13% -$732K ﹤0.01% 2934
2016
Q4 		$5.86M Sell
43,047
-1,103
-2% -$196K ﹤0.01% 2829
2016
Q3 		$8.79M Buy
44,150
+2,916
+7% +$502K ﹤0.01% 2132
2016
Q2 		$5.34M Sell
41,234
-133
-0.3% -$14.8K ﹤0.01% 2555
2016
Q1 		$3.87M Sell
41,367
-1,319
-3% -$144K ﹤0.01% 2765
2015
Q4 		$8.65M Buy
42,686
+7,445
+21% +$1.33M ﹤0.01% 2113
2015
Q3 		$5.12M Buy
35,241
+31,395
+816% +$5.76M ﹤0.01% 2640
2015
Q2 		$818K Buy
3,846
+492
+15% +$121K ﹤0.01% 4353
2015
Q1 		$777K Sell
3,354
-11,673
-78% -$2.82M ﹤0.01% 4322
2014
Q4 		$3.46M Buy
+15,027
New +$3.22M ﹤0.01% 3068

Other funds holding BLCM

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Morgan Stanley's BLCM Position: Q2 2023 in Review

Morgan Stanley sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 13,962 shares — an estimated $4.61K sold.

Morgan Stanley first reported a position in BLCM in Q4 2014 and held it in 34 quarters. The position peaked at $8.79M in Q3 2016. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

  • Morgan Stanley reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Morgan Stanley sold 13,962 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $4.61K.
  • Morgan Stanley first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 34 quarters.
  • Morgan Stanley's Bellicum Pharmaceuticals, Inc. position peaked at $8.79M in Q3 2016.
  • 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.